Magnetic resonance imaging (MRI) has had a profound impact on both research and clinical management of multiple sclerosis (MS), but signal changes reflect underlying neuropathology only indirectly and often non-specifically. Positron emission tomography (PET) offers the potential to complement MRI with quantitative measures of molecularly specific markers of cellular and metabolic processes. PET radiotracers already available promise new insights into the dynamics of the innate immune response, neuronal function, neurodegeneration and remyelination. Because PET is an exquisitely sensitive technique (able to image even picomolar concentrations), only microdoses of radioligand (<10 µg) are needed for imaging. This facilitates rapid implementation of novel radioligands because extensive toxicology data is not required. In the future, molecular imaging could assist clinical decision-making with patient stratification for optimization of treatment selection.
MillerDHFilippiMFazekasFFrederiksenJLMatthewsPMMontalbanX. Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis. Ann Neurol2004; 56: 273–278.
2.
BarkhofFCalabresiPAMillerDHReingoldSC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol2009; 5: 256–266.
3.
ArnoldDLMatthewsPM. MRI in the diagnosis and management of multiple sclerosis. Neurology2002; 58(Suppl 4): S23–S31.
4.
GuoQBradyMGunnRN. A biomathematical modeling approach to central nervous system radioligand discovery and development. J Nucl Med2009; 50: 1715–1723.
5.
ThieJA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med2004; 45: 1431–1434.
6.
TurkheimerFEEdisonPPaveseNRoncaroliFAndersonANHammersA. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med2007; 48: 158–167.
7.
VennetiSLoprestiBJWileyCA. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol2006; 80: 308–322.
8.
KreutzbergGW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci1996; 19: 312–318.
9.
GehrmannJMatsumotoYKreutzbergGW. Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev1995; 20: 269–287.
10.
BenvenisteEN. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med1997; 75: 165–173.
BruckWPoradaPPoserSRieckmannPHanefeldFKretzschmarHA. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol1995; 38: 788–796.
13.
LacapereJJPapadopoulosV. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids2003; 68: 569–585.
14.
DobleAMalgourisCDanielMDanielNImbaultFBasbaumA. Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: anatomical and subcellular distribution. Brain Res Bull1987; 18: 49–61.
15.
PapadopoulosVBaraldiMGuilarteTRKnudsenTBLacapereJJLindemannP. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci2006; 27: 402–409.
16.
MaedaJHiguchiMInajiMJiBHanedaEOkauchiT. Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res2007; 1157: 100–111.
17.
JiBMaedaJSawadaMOnoMOkauchiTInajiM. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer’s and other CNS pathologies. J Neurosci2008; 28: 12255–12267.
18.
ShahFHumeSPPikeVWAshworthSMcDermottJ. Synthesis of the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl Med Biol1994; 21: 573–581.
19.
GerhardAPaveseNHottonGTurkheimerFEsMHammersA. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis2006; 21: 404–412.
20.
RamsaySCWeillerCMyersRCremerJELuthraSKLammertsmaAA. Monitoring by PET of macrophage accumulation in brain after ischaemic stroke. Lancet1992; 339: 1054–1055.
21.
CagninAMyersRGunnRNLawrenceADStevensTKreutzbergGW. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain2001; 124: 2014–2027.
22.
EdisonPArcherHAGerhardAHinzRPaveseNTurkheimerFE. Microglia, amyloid, and cognition in Alzheimer’s disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis2008; 32: 412–419.
23.
BanatiRBNewcombeJGunnRNCagninATurkheimerFHeppnerF. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain2000; 123: 2321–2337.
24.
ChenMKBaidooKVerinaTGuilarteTR. Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain2004; 127: 1379–1392.
25.
DebruyneJCVersijptJVan LaereKJDeVFKeppensJStrijckmansK. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol2003; 10: 257–264.
26.
VersijptJDebruyneJCVan LaereKJDeVFKeppensJStrijckmansK. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler2005; 11: 127–134.
27.
RaoSMLeoGJBernardinLUnverzagtF. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology1991; 41: 685–691.
28.
BarkhofF. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol2002; 15: 239–245.
29.
CifelliAArridgeMJezzardPEsiriMMPalaceJMatthewsPM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol2002; 52: 650–653.
30.
BoLVedelerCANylandHITrappBDMorkSJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol2003; 62: 723–732.
31.
KutzelniggALucchinettiCFStadelmannCBruckWRauschkaHBergmannM. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain2005; 128: 2705–2712.
32.
CalabreseMRoccaMAAtzoriMMattisiIFavarettoAPeriniP. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol2010; 67: 376–383.
33.
BagnatoFSalmanZKaneRAuhSCantorFKEhrmantrautM. T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis. Mult Scler2010; 16: 1203–1212.
34.
MaineroCBennerTRaddingAvan derKAJensenRRosenBR. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology2009; 73: 941–948.
35.
BagnatoFYaoBCantorFMerkleHCondonEMontequinM. Multisequence-imaging protocols to detect cortical lesions of patients with multiple sclerosis: observations from a post-mortem 3 Tesla imaging study. J Neurol Sci2009; 282: 80–85.
36.
SchmiererKParkesHGSoPWAnSFBrandnerSOrdidgeRJ. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Brain2010; 133: 858–867.
37.
VercellinoMMerolaAPiacentinoCVottaBCapelloEMancardiGL. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol2007; 66: 732–739.
38.
PolitisMGiannettiPSuPTurkheimerFKeihaninejadSWuK. Cortical microglial activation is associated with disability in secondary progressive multiple sclerosis: An in vivo imaging study. Neurology2010; 74(Suppl 2): A290.
39.
ChauveauFBoutinHVanCNDolleFTavitianB. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging2008; 35: 2304–2319.
40.
FujimuraYZoghbiSSSimeonFGTakuAPikeVWInnisRB. Quantification of translocator protein (18 kDa) in the human brain with PET and a novel radioligand, (18)F-PBR06. J Nucl Med2009; 50: 1047–1053.
41.
WilsonAAGarciaAParkesJMcCormickPStephensonKAHouleS. Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol2008; 35: 305–314.
42.
IkomaYYasunoFItoHSuharaTOtaMToyamaH. Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [(11)C]DAA1106. J Cereb Blood Flow Metab2007; 27: 173–184.
43.
EndresCJPomperMGJamesMUzunerOHammoudDAWatkinsCC. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med2009; 50: 1276–1282.
44.
FookesCJPhamTQMattnerFGreguricILoc’hCLiuX. Synthesis and biological evaluation of substituted [18F]imidazo[1,2-a]pyridines and [18F]pyrazolo[1,5-a]pyrimidines for the study of the peripheral benzodiazepine receptor using positron emission tomography. J Med Chem2008; 51: 3700–3712.
45.
Van CampNBoisgardRKuhnastBThezeBVielTGregoireMC. In vivo imaging of neuroinflammation: a comparative study between [(18)F]PBR111, [(11)C]CLINME and [(11)C]PK11195 in an acute rodent model. Eur J Nucl Med Mol Imaging2010; 37: 962–972.
46.
ImaizumiMBriardEZoghbiSSGourleyJPHongJFujimuraY. Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neuroimage2008; 39: 1289–1298.
47.
FujitaMImaizumiMZoghbiSSFujimuraYFarrisAGSuharaT. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage2008; 40: 43–52.
48.
OwenDRHowellOWTangSPWellsLABennacefIBergstromM. Two binding sites for [(3)H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab2010; 30: 1608–1608.
49.
David RJ Owen, Roger N Gunn, Eugenii A Rabiner, Idriss Bennacef, Masahiro Fujita, William C Kreisl, et al. Mixed Affinity Binding in Humans with 18 kDa Translocator Protein (TSPO) Ligands. J Nucl Med 2010. [In Press].
50.
KreislWCFujitaMFujimuraYKimuraNJenkoKJKannanP. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage2010; 49: 2924–2932.
51.
DoussetVBrochetBDeloireMSLagoardeLBarrosoBCailleJM. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol2006; 27: 1000–1005.
52.
BendszusMStollG. Caught in the act: in vivo mapping of macrophage infiltration in nerve injury by magnetic resonance imaging. J Neurosci2003; 23: 10892–10896.
53.
KleinschnitzCBendszusMFrankMSolymosiLToykaKVStollG. In vivo monitoring of macrophage infiltration in experimental ischemic brain lesions by magnetic resonance imaging. J Cereb Blood Flow Metab2003; 23: 1356–1361.
54.
CabralGAGriffin-ThomasL. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med2009; 11: e3.
55.
HerkenhamMLynnABLittleMDJohnsonMRMelvinLSde CostaBR. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A1990; 87: 1932–1936.
56.
GaliegueSMarySMarchandJDussossoyDCarriereDCarayonP. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem1995; 232: 54–61.
57.
CarlisleSJMarciano-CabralFStaabALudwickCCabralGA. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol2002; 2: 69–82.
58.
MareszKCarrierEJPonomarevEDHillardCJDittelBN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem2005; 95: 437–445.
59.
BenitoCRomeroJPTolonRMClementeDDocagneFHillardCJ. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci2007; 27: 2396–2402.
60.
EvensNMuccioliGGHoubrechtsNLambertDMVerbruggenAMVanLK. Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging. Nucl Med Biol2009; 36: 455–465.
61.
HortiAGGaoYRavertHTFinleyPValentineHWongDF. Synthesis and biodistribution of [(11)C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB(2)). Bioorg Med Chem2010; 18: 5202–5207.
62.
Dubois-DalcqMWilliamsAStadelmannCStankoffBZalcBLubetzkiC. From fish to man: understanding endogenous remyelination in central nervous system demyelinating diseases. Brain2008; 131: 1686–1700.
63.
HenkelmanRMStaniszGJGrahamSJ. Magnetization transfer in MRI: a review. NMR Biomed2001; 14: 57–64.
64.
SchmiererKWheeler-KingshottCABoulbyPAScaravilliFAltmannDRBarkerGJ. Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage2007; 35: 467–477.
65.
LauleCVavasourIMKolindSHLiDKTraboulseeTLMooreGR. Magnetic resonance imaging of myelin. Neurotherapeutics2007; 4: 460–484.
66.
StankoffBWangYBottlaenderMAigrotMSDolleFWuC. Imaging of CNS myelin by positron-emission tomography. Proc Natl Acad Sci U S A2006; 103: 9304–9309.
67.
WangYWuCCaprarielloAVSomozaEZhuWWangC. In vivo quantification of myelin changes in the vertebrate nervous system. J Neurosci2009; 29: 14663–14669.
68.
SokoloffL. Energetics of functional activation in neural tissues. Neurochem Res1999; 24: 321–329.
69.
SchiepersCVanHPVandenbergheRVanOSDupontPDemaerelP. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler1997; 3: 8–17.
70.
RaduCGShuCJNair-GillEShellySMBarrioJRSatyamurthyN. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2’-deoxycytidine analog. Nat Med2008; 14: 783–788.
71.
SokoloffL. Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. J Cereb Blood Flow Metab1981; 1: 7–36.
72.
BakshiRMiletichRSKinkelPREmmetMLKinkelWR. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging1998; 8: 228–234.
73.
RoelckeUKapposLLechner-ScottJBrunnschweilerHHuberSAmmannW. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology1997; 48: 1566–1571.
74.
BlinkenbergMRuneKJensenCVRavnborgMKyllingsbaekSHolmS. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology2000; 54: 558–564.
75.
BlinkenbergMJensenCVHolmSPaulsonOBSorensenPS. A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS. Neurology1999; 53: 149–153.
76.
PaulesuEPeraniDFazioFComiGPozzilliCMartinelliV. Functional basis of memory impairment in multiple sclerosis: a[18F]FDG PET study. Neuroimage1996; 4: 87–96.
77.
HeissWDGrondMThielAGhaemiMSobeskyJRudolfJ. Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. Stroke1998; 29: 454–461.
78.
LloydCMRichardsonMPBrooksDJAl-ChalabiALeighPN. Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain2000; 123: 2289–2296.
79.
OhyamaMSendaMIshiwataKKitamuraSMishinaMIshiiK. Preserved benzodiazepine receptors in Alzheimer’s disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med1999; 13: 309–315.
80.
MuraiHKiyosawaMSuzukiYMizoguchiSIshiiKIshikawaK. A case of multiple sclerosis with homonymous hemianopia examined by positron emission tomography. Jpn J Ophthalmol2004; 48: 591–593.
GreeneYMTariotPNWishartHCoxCHoltCJSchwidS. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol2000; 20: 350–356.
83.
KruppLBChristodoulouCMelvillePScherlWFMacAllisterWSElkinsLE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology2004; 63: 1579–1585.
84.
VolkowNDDingYSFowlerJSGatleySJ. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer’s dementia. Biol Psychiatry2001; 49: 211–220.
